Venky Ramakrishna, PhD

Immunology Consultant
P. O. Box 423, Riegelsville
PA 18077-0423, USA

E-mail: vr.immcon@gmail.com

Biography

Education

• PhD in Tumor Immunology, Weizmann Institute of Science, Rehovot, Israel
• Visiting Scientist, Indian Institute of Science, Bangalore, India
• Master of Technology in Biotechnology, Indian Institute of Technology, Kharagpur, India
• Master of Science in Botany, University of Bangalore, Bangalore, India

Research Interest

His research interests: Antigen discovery, Proteomics, Translational biomarkers, Clinical development, Intellectual property, Regulatory submission, Market access.

Scientific Activities

Publications

1. Ramakrishna V, Shinitzky, M. Potentiation of delayed-type hypersensitivity response to syngeneic tumors in mice prevaccinated with cells modified by pressure and crosslinking. Cancer Immunol Immunother. 1991; 33(1): 1-8. doi: 10.1007/BF01742520
2. Shinitzky M, Ramakrishna V. Hydrostatic pressure: Effects on immune system. In: Roitt IP, Delves PJ, eds. Encyclopaedia of Immunology. NY, USA: Academic Press (HBJ): 1992; 709-711.
3. Ramakrishna V, Eisenthal A, Shinitzky M. Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking. Cancer Immunol Immunother. 1993; 36(3): 293-299. doi: 10.1007/BF01741167
4. Eisenthal A, Ramakrishna V, Skornick Y, Shinitzky M. Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking. Cancer Immunol Immunother. 1993; 36(3): 300-306. doi: 10.1007/BF01741168
5. Eisenthal, A., Kashtan, H., Ramakrishna V, Rabau, M., and Skornick, Y. Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells. Cancer Immunol Immunother. 1993; 36(2): 101-107. doi: 10.1007/BF01754409
6. Shinitzky M, Eisenthal A, Ramakrishna V, Abulafia R. Tumor vaccines–Perspectives and practice. In: Cittadini A, Baserga R, Pinedo HM, Galeotti T, Corda D, eds. Molecular and Cell Biology Updates Series: Molecular Oncology and Clinical Applications. Basel, Switzerland: Birkhäuser Verlag; 1993: 297-311.
7. Corda D, Falasca M, Iacovelli, A, Carvelli A, D’Arcangelo D, Ramakrishna V. Novel cellular activities of phosphoinositide metabolites originated by the action of phospholipase A2. In: Corda D, Hamm H, Luini A, eds. GTPase-Controlled Molecular Machines. Milano, Italy: Ares-Serono Symposium; 1994: 79-94.
8. Ramakrishna V, Falasca M, Carvelli A, Corda D. Inhibition of phospholipase A2 by glycerophosphoinositols in cell lines of different origin (Patent Document).
9. Falasca M, Silletta MG, Carvelli A, Di Francesco AL, Fusco A, Ramakrishna V et al. Signalling pathways invovled in the mitogenic action of lysophosphatidylinositol. Oncogene. 1995; 10: 2113-2124.
10. Canevari S, Mezzanzanica D, Mazzoni A, Negri DRM, Ramakrishna V, Bolhuis RLH, et al. Bispecific antibody targeted T cell therapy of ovarian cancer: Clinical results and future directions. J Hematother. 1995; 4: 423-427. doi: 10.1089/scd.1.1995.4.423
11. Ramakrishna V, Negri DRM, Brusic V, Fontanelli R, Canevari S, Bolis G, et al. Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. Int J Cancer. 1997; 73: 143-150. doi: 10.1002/(sici)1097-0215(19970926)73:1<143::aid-ijc22>3.0.co;2-g
12. Botti C, Negri DRM, Seregni E, Ramakrishna V, Arienti F, Maffioli L, et al. Comparison of three different methods for radiolabeling human activated T lymphocytes. Eur J Nucl Med. 1997; 24: 497-504. doi: 10.1007/BF01267680
13. Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, et al. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 1998; 58: 4146-4154.
14. Flyer DC, Ramakrishna V, Myers CL, McDaniel HM, Root M, Flournoy K, et al. Identification of CD8+ T cell M. tuberculosis epitopes within the Rv0341 gene product by mass spectrometry. Infect and Immun. 2002; 70: 2926-2932.
15. Ramakrishna V, Treml JF, Vitale L, Connolly JE, O’Neill T, Smith PA, et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol. 2004; 172: 2845-2852. doi: 10.4049/jimmunol.172.5.2845
16. Ramakrishna V et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted T cells. Int Immunol. 2003; 15(6): 751-763. doi: 10.1093/intimm/dxg074
17. He L-Z, Ramakrishna V, Connolly JE, Wang X-T, Smith PA, Jones CL, et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin b. Clinical Cancer Res. 2004; 10: 1920-1927. doi: 10.1158/1078-0432.ccr-03-0264
18. Keler T. Ramakrishna V and Fanger, MW. Mannose receptor-targeted vaccines. Expert Opin Biol Ther. 2004; 4(12): 1953-1962. doi: 10.1517/14712598.4.12.1953
19. Keler T, He L, Ramakrishna V, Champion B. Antibody-targeted vaccines (Review). Oncogene. 2007; 26: 3758-3767. doi:10.1038/sj.onc.1210375
20. Ramakrishna V, Vasilakos JP, Tario Jr. JD, Berger MA, Wallace PK, Keler T. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting.) human dendritic cells. J Transl Med. 2007; 5: 5. doi: 10.1186/1479-5876-5-5
21. Neethling FA, Ramakrishna V, Keler T, Buchli R, Weidanz JA. Assessing vaccine potency using TCR mimic antibodies. Vaccine. 2008; 26(25): 3092-3102. doi: 10.1016/j.vaccine.2008.02.025
22. Morse MA, Chapman R, Powderly J, Blackwell K, Keler T, Green J, et al. Phase I Study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self antigens in cancer patients. Clin Cancer Res. 2011; 17(14): 4844-4853. doi: 10.1158/1078-0432.CCR-11-0891
23. Tsujit T, Matsuzaki J, Kelly MP, Ramakrishna V, Vitale L, He L-Z, et al. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol. 2011; 186: 1218-1227. doi: 10.4049/jimmunol.1000808
24. Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, et al. Induction of antigen-specific immunity following vaccine targeting NY-ESO1 to dendritic cell receptor, DEC205. Sci Transl Med. 2014; 6(232): 232ra51. doi: 10.1126/scitranslmed.3008068